Barclays analyst Peter Lawson maintained a Buy rating on Epizyme (EPZM – Research Report) on January 13 and set a price target of $4.00. The company’s shares closed last Friday at $2.17, close to its 52-week low of $2.16.
According to TipRanks.com, Lawson is a 3-star analyst with an average return of 4.2% and a 43.3% success rate. Lawson covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Karyopharm Therapeutics, and Prelude Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Epizyme with a $10.33 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $12.69 and a one-year low of $2.16. Currently, Epizyme has an average volume of 1.63M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.
Read More on EPZM:
- Coca-Cola Europacific Partners (CCEP) Receives a Buy from Barclays
- Barclays Reaffirms Their Buy Rating on Mondelez International (MDLZ)
- Barclays Maintains Their Buy Rating on Vale SA (VALE)
- Hain Celestial (HAIN) Gets a Hold Rating from Barclays
- Barclays Believes Procter & Gamble (PG) Won’t Stop Here
